c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerUrinary cytokine and chemokine profiles across the menstrual cycle in healthy reproductive-aged women.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancerHGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Cellular responses to Cisplatin-induced DNA damage.Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.Cisplatin in cancer therapy: molecular mechanisms of actionHGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancerOverexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.MicroRNA-185 inhibits proliferation by targeting c-Met in human breast cancer cells.p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation.Anoikis mediators in oral squamous cell carcinoma.Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cellsMet receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions.Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.The interconnectedness of cancer cell signaling.Gene transcripts associated with BMI in the motor cortex and caudate nucleus of calorie restricted rhesus monkeys.Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDXc-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell modelsMiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.Ovarian cancer molecular pathology.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Oncogenes associated with drug resistance in ovarian cancer.cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells.Function and regulation of microRNA-31 in development and disease.Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC.Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis.Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways.
P2860
Q24628746-C3E284F5-3D32-4BE4-9004-D5A59D68291BQ33560975-686B69F6-E351-4C3A-9952-9F116B46F2D7Q33886974-2E83C451-6D1F-4497-B8F0-90E76D6410E5Q33917507-C28E1A66-7C1D-4288-9895-32CAC2641D65Q34089685-E7199500-CAAC-4FEA-95E5-ED6EC32C0935Q34096767-502833E6-52D3-47C7-A22A-A7EC7D409D37Q34098163-73DA13E5-05C4-4A6F-BDBF-451C2E801EC3Q34104074-1EF8866E-91A6-492D-AFB7-2A01004FD47EQ34391763-1B76C7C1-9DEB-4D80-BEB9-71D97C07F99DQ34444017-06FC7CCA-F4BB-4E65-B802-70D6ADBA1479Q34619266-890FFC8C-55CB-4C52-A3E2-3E56EF48EEF3Q34770470-94C47ECD-AFBE-4BAE-86EC-35B48DB96B9BQ35033660-5FA863FB-0CCE-46E6-94AC-D13FEBA90575Q35051630-BAA9A79C-F3F5-41FA-BE20-86D096B6FD60Q35141465-F1CFE923-A262-4BA1-9A1F-05F2B07370DCQ35203637-1064DD37-3E8D-45C8-8F94-05DC061BF287Q35669733-93007A28-BCF4-419C-9E04-8BEE1A5F2C39Q35798910-0BC8DA3C-FE2F-4812-BE8F-2CB8131BD092Q36286844-E6DDF2F2-0594-448F-8573-3AF75F2B9A74Q36354166-860D5AF7-B9E7-406A-ABAF-1E0B1A726A67Q36520263-75C3C446-C77A-4A16-88A7-FB3679474D2BQ36809577-4829953A-206F-4F51-A350-E4EA6B6C6BADQ37346174-9C5E460B-5B4B-4926-8B6E-D6EAC38C4DFFQ37472110-E2C19F18-1819-40E5-9428-3201FDB559F1Q37502372-354D617C-344B-4E8F-B29F-B99B31FB8A42Q37687364-97DF4E71-11FF-48CD-8646-B4375C77BE43Q38021356-4B4F0E3B-FBC5-45AB-8F26-0D685A5E8E51Q38175044-4FF7771D-2BD6-4497-89EA-9944FD627501Q38226577-A69F07A8-0D5A-42D7-9051-D2D23EAF4B8EQ38393333-CF665264-8880-4FD2-8ED1-3CD5E8185E0EQ38774306-B495462A-23FE-42F0-AA26-FCE877476D0FQ38893973-70E1BD39-4636-404D-B33D-84A96836015CQ38896144-8F8A39EE-5E40-4E0B-BA7C-F5EAEF0DD33AQ38913406-C704E1F5-B432-4792-803C-6F933042612BQ38996033-85261450-76EB-4E26-8EFC-3E95E6010380Q39036241-B960FCA4-DA91-4C42-98F1-CA0F0A0DFD91Q39412894-6C994D7E-D4E5-4B6C-851E-738AA871B3B5Q39449455-29476585-6859-4951-899E-3F2FB27F8C31Q39458573-A852B88A-7622-4CBE-B035-DA9520171B0AQ39699566-4CB2E3A4-D329-4F7F-8064-BA2CE81C828C
P2860
c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@ast
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@en
type
label
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@ast
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@en
prefLabel
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@ast
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@en
P2093
P2860
P921
P356
P1433
P1476
c-Met overexpression contribut ...... r signal-regulated kinase 1/2.
@en
P2093
Alice S T Wong
Hong Y Zhou
Judy W P Yam
Maggie K S Tang
P2860
P304
P356
10.1593/NEO.91438
P577
2010-02-01T00:00:00Z